69491-64-1

Basic information

• Product Name: 3-FLUORO-BENZAMIDINE
• Synonyms: 3-FLUORO-BENZAMIDINE;CHEMBRDG-BB 4017632;3-FLUOROBENZENECARBOXIMIDAMIDEHYDROCHLORIDE;3-fluorobenzenecarboximidamide(SALTDATA: HCl 0.05C4H8O 0.05C4H8O2);3-Fluorobenzenecarboximidamide;m-Fluorobenzamidine;BenzenecarboxiMidaMide, 3-fluoro-;3-FluorobenziMidaMide
• CAS NO: 69491-64-1
• Molecular Formula: C₇H₇FN₂
• Molecular Weight: 138.14
• EINECS: 604-604-1
• Mol File: 69491-64-1.mol
• Article Data: 7

Chemical Properties

• Boiling Point: 214℃
• Flash Point: 83℃
• Appearance: /
• Density: 1.22
• Storage Temp.: Keep in dark place,Inert atmosphere,Room temperature
• CAS DataBase Reference: 3-FLUORO-BENZAMIDINE(CAS DataBase Reference)
• NIST Chemistry Reference: 3-FLUORO-BENZAMIDINE(69491-64-1)
• EPA Substance Registry System: 3-FLUORO-BENZAMIDINE(69491-64-1)

Safety Data

• Hazardous Substances Data: 69491-64-1(Hazardous Substances Data)

Usage

Uses

3-Fluorobenzamidine

Upstream product

• 403-54-3 m-Fluorobenzonitrile 

Downstream Products

• 684220-41-5 6-butyl-2-(3-fluorophenyl)-3H-pyrimidin-4-one 
• 1026484-41-2 5-Chloromethyl-2-(3-fluoro-phenyl)-1H-imidazole 
• 1001755-39-0 [2-(3-Fluoro-phenyl)-3H-imidazol-4-yl]-methanol 
• 76128-80-8 <2-(m-fluorophenyl)-4-pyrimidyl>trimethylammonium chloride 
• 76128-77-3 4-cyano-2-(m-fluorophenyl)pyrimidine 
• 76144-35-9 4-dimethylamino-2-(m-fluorophenyl)pyrimidine 
• 76128-74-0 4-methoxy-2-(m-fluorophenyl)pyrimidine 
• 76128-72-8 4-bromo-2-(m-fluorophenyl)pyrimidine 
• 76128-70-6 4-chloro-2-(m-fluorophenyl)pyrimidine 

Relevant articles and documents

Novel Allosteric Inhibitors of Deoxyhypusine Synthase against Malignant Melanoma: Design, Synthesis, and Biological Evaluation

Based on the novel allosteric site of deoxyhypusine synthase (DHPS), two series of 30 novel 5-(2-methoxyphenoxy)-2-phenylpyrimidin-4-amine derivatives as DHPS inhibitors were designed and synthesized. Among them, compound8m, with the best DHPS inhibitory potency (IC50= 0.014 μM), exhibited excellent inhibition against melanoma cells, which was superior to that of GC7. Besides, molecular docking and molecular dynamics (MD) simulations further proved that compound8mwas tightly bound to the allosteric site of DHPS. Flow cytometric analysis and enzyme-linked immunosorbent assay (ELISA) showed that compound8mcould inhibit the intracellular reactive oxygen species (ROS) level. Furthermore, by western blot analysis, compound8meffectively activated caspase 3 and decreased the expressions of GP-100, tyrosinase, eIF5A2, MMP2, and MMP9. Moreover, both Transwell analysis and wound healing analysis showed that compound8mcould inhibit the invasion and migration of melanoma cells. In thein vivostudy, the tumor xenograft model showed that compound8meffectively inhibited melanoma development with low toxicity.

NOVEL COMPOUNDS

This invention relates to compounds of formula I their use as positive allosteric modulators of mGlu5 receptor activity, pharmaceutical compositions containing the same, and methods of using the same as agents for treatment and/or prevention of neurological and psychiatric disorders associated with glutamate dysfunction such as schizophrenia or cognitive decline such as dementia or cognitive impairment. A, B, Ar, R1, R2, R3 have meanings given in the description.

DIPEPTIDYL PEPTIDASE-IV INHIBITING COMPOUNDS, METHODS OF PREPARING THE SAME, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME AS AN ACTIVE AGENT

The present invention relates to novel compounds exhibiting good inhibitory activity versus Dipeptidyl Peptidase-IV(DPP-IV), methods of preparing the same and pharmaceutical compositions containing the same as an active agent.